CM Management LLC Increases Stock Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)

CM Management LLC grew its stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 160,000 shares of the company’s stock after purchasing an additional 15,941 shares during the quarter. CM Management LLC owned approximately 0.96% of Coya Therapeutics worth $917,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Newbridge Financial Services Group Inc. purchased a new position in shares of Coya Therapeutics during the fourth quarter worth about $401,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Stock Performance

COYA stock opened at $6.88 on Friday. Coya Therapeutics, Inc. has a one year low of $4.75 and a one year high of $10.69. The company has a fifty day moving average of $6.20 and a 200-day moving average of $6.45. The stock has a market capitalization of $114.94 million, a PE ratio of -10.58 and a beta of 0.31.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on COYA shares. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Thursday, February 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, February 6th.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.